Search results: (10000)
News Mucormycosis Associated with COVID-19 – Case Report and Review of Current Knowledge
Systemic corticosteroids are among the treatments used for patients with severe COVID-19. These patients are at increased risk of opportunistic bacterial and fungal infections. Pulmonary aspergillosis is particularly serious, while mucormycosis is relatively rare.
News Neuroprotective Efficacy and Safety of Vinpocetine in Patients with Acute Ischemic Stroke
A meta-analysis of 4 randomized placebo-controlled studies demonstrated the benefits of vinpocetine in patients with ischemic stroke (iCMP). Administering vinpocetine within 14 days of the onset of the stroke significantly reduced the level of disability and the proportion of those who died or were dependent on others after 1 and 3 months. The results showed benefits in several other parameters and indicated very good tolerability of this drug used to increase cerebral blood flow.
News Treatment of a patient with colorectal cancer after kidney transplantation – case report
Patients after organ transplantation currently live to an older age thanks to advances in surgery and pharmacotherapy. However, the longer a person takes immunosuppressants, the more they are at risk of developing malignant disease. The case report of Hungarian doctors from the university hospital in Pécs illustrates what the treatment of metastatic colorectal cancer (mCRC) after kidney transplantation can look like.
News Li-Fraumeni Syndrome – Indication for Testing and Recommended Surveillance
A germline mutation of the TP53 gene, which causes Li-Fraumeni syndrome, results in a congenital predisposition to the occurrence of malignant tumors, such as pediatric malignancies, breast cancer, bone sarcomas, and others. We bring a summary of indications for testing the pathogenic variant of the TP53 gene according to the recommendations of the National Comprehensive Cancer Network (NCCN) and the surveillance program for carriers of this variant according to the consensus of the current recommendations of the European, American, Japanese, and Australian scientific societies compared to the recommendations of the Czech Oncology Society ČLS JEP.
News Long-term survival of a 50-year-old man with metastatic pancreatic cancer on a combination of nal-IRI + 5-FU/LV in 2nd line treatment − case study
A recently published case study from the Czech Republic describes a patient with progression of pancreatic cancer following surgical treatment and adjuvant chemotherapy, who achieved a one-year survival with good quality of life on a combination of nal-IRI + 5-FU/LV after the failure of gemcitabine + nab-paclitaxel in the 1st line of palliative treatment.
News The Benefit of Liposomal Irinotecan in the Treatment of Pancreatic Cancer in a Young Patient – A Case Study
Pancreatic tumors continue to be a challenge in modern oncology. Due to the asymptomatic nature of early stages, most cases are diagnosed in advanced stages. The five-year survival rate of patients does not even reach 10%, and up to half of patients with metastatic pancreatic cancer never make it to the second line of systemic therapy due to the rapid deterioration of their overall clinical condition. In a case study from her own practice, Dr. Marie Beneš Kočová from the Oncology Department of České Budějovice Hospital shared her experience with the treatment of a relatively early-detected disease in a young patient.
News Side Effects of Antipsychotics and Patient Preferences in the Treatment of Schizophrenia
Although a number of antipsychotics are currently available, many patients still suffer from unpleasant side effects associated with the treatment of schizophrenia. To determine how individuals with schizophrenia and schizoaffective disorders perceive antipsychotic treatment, a larger survey was conducted in the USA in 2016.
News Efficacy and Safety of the Combination of Telmisartan and Amlodipine with Hydrochlorothiazide in the Treatment of Hypertension
The aim of the study by Korean authors was to evaluate the efficacy and tolerability of the triple combination of telmisartan/amlodipine + hydrochlorothiazide (TAH) compared to the combination of telmisartan/amlodipine (TA) alone in patients with essential hypertension who did not respond sufficiently to a 4-week treatment with TA.
News Current Legislative Changes Relating to Medical Devices – Overview Summary in a Nutshell
In 2022, several legislative changes were introduced in the area of medical devices (MD) for moist wound care. We are summarizing the news from three sectors, as presented by Mgr. Jan Zahálka at the Interdisciplinary Cooperation in the Treatment of Wounds and Skin Defects congress in 2022: prescribing MD by nurses, European Union Medical Device Regulation (MDR), and the issue of MD as potential hazardous waste.
News Critical Conditions in Obstetrics 2022: What is Available in the Czech Republic for Managing Peripartum Life-Threatening Bleeding?
On December 10, 2022, a professional meeting entitled Critical Conditions in Obstetrics 2022 was held in the lecture hall of the new building of the National Museum in Prague. Prof. MUDr. Antonín Pařízek, CSc., from the Department of Gynecology and Obstetrics of the 1st Faculty of Medicine, Charles University, and General University Hospital in Prague, gave a presentation addressing the issue of peripartum life-threatening bleeding (PLTB), the necessities for its management, and provided an overall perspective on the current situation in obstetrics in our country.
News Rapid Strengthening and Long-term Stabilization – New Strategy for Sequential Treatment of Severe Osteoporosis
Osteoanabolics have long been considered a treatment modality for osteoporosis that is only considered when antiresorptive medication lacks the desired efficacy. However, their role has been shifting in recent years based on new findings from clinical research, as evidenced by the conclusions of the expert working group of the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis, and Musculoskeletal Diseases (ESCEO), whose brief summary we bring.
News Transition from Risperidone to Lurasidone and Adjustment of Metabolic Profile in Patients with Stable Schizophrenia
Patients with schizophrenia have a higher risk of cardiometabolic diseases compared to the general population, which is further increased by certain antipsychotics. A recently published post hoc analysis assessed, among other things, the metabolic parameters of patients who switched from risperidone therapy to lurasidone.
News Subcutaneous vs. Intravenous Immunoglobulins in Patients with CLL
Secondary antibody immunodeficiency is a common complication in patients with chronic lymphocytic leukemia (CLL), and infections, along with secondary malignancies, are the leading cause of death in these patients. Hypogammaglobulinemia can be managed with immunoglobulin replacement therapy (IGRT). Besides the classic intravenous form (IVIG), a subcutaneous form (SCIG) is also available. An Italian retrospective study published in the journal Current Oncology compared their efficacy in secondary immunodeficiency in CLL patients.
News Current and Future Possibilities for Influencing Immune Thrombocytopenia
The possibilities for treating immune thrombocytopenia (ITP) are quite broad today, with a major advancement for many patients being the advent of thrombopoietin receptor agonists. However, for some patients, optimal treatment is still not available, and their hope lies in further research.
News Dupilumab Now Covered for Atopic Dermatitis in Children Older Than 6 Years
Dupilumab is now fully covered by public health insurance for pediatric patients from 6 years old with atopic dermatitis. This opens up a new possibility for pediatric patients with this condition to improve their quality of life.
News Is Dupilumab Effective in AD Therapy for Patients for Whom Cyclosporine A Fails or Cannot Be Given?
Severe forms of atopic dermatitis (AD) may require systemic therapy. However, the immunosuppressant cyclosporine A does not have sufficient efficacy in some patients with AD or is contraindicated for them. Therefore, the phase III clinical trial LIBERTY AD CAFÉ evaluated the efficacy of dupilumab in these patients.
News Perioperative Management in Patients with Atrial Fibrillation Treated with NOACs
The recommended procedures for perioperative management in patients using novel oral anticoagulants (NOACs) stem from the requirement to minimize treatment interruption before and after surgical procedures to reduce the risk of bleeding and thromboembolism. The safety of these regimens in patients with atrial fibrillation was examined in the prospective PAUSE study presented below.
News Inosine pranobex in the treatment of influenza and other respiratory infections of viral etiology
The antiviral inosine pranobex is a clinically proven immunomodulator for the treatment of patients from 1 year of age, indicated for a wide range of diseases with manifestations of immune insufficiency and viral infections. It acts by a direct antiviral effect, modulates the immune system, and also finds application in the treatment of acute viral respiratory diseases, such as influenza and other seasonal viral infections.
News Screening using NGS in patients with metastatic NSCLC – initial results from the ALK-positive cohort
Next-generation sequencing (NGS) allows for obtaining a large amount of information about the tumor genome from a patient's blood sample. Currently, the method is recommended as an alternative in cases of insufficient tissue samples for standard biopsy examination. The first results of an ongoing prospective study provide insights into the role of NGS in mutation screening for patients with non-small cell lung cancer without a concurrent biopsy examination.
News Algorithm for Choosing Antidiabetics in Patients with Type 2 Diabetes
As of June 1, 2020, general practitioners can prescribe antidiabetics from the group of so-called gliptins, inhibitors of the enzyme dipeptidyl peptidase 4 (DPP-4i), in addition to metformin. The cornerstone of type 2 diabetes mellitus treatment remains a comprehensive lifestyle modification (dietary measures, increased physical activity, weight reduction) and metformin as the first-line drug. In selected comorbidities or if these measures do not lead to the desired glycated hemoglobin (HbA1c) level after 3-6 months, the following recommendations can be followed. However, it is essential to remember that the recommendations of professional societies do not always correspond to the prescription limitations of the State Institute for Drug Control (SÚKL).